ArticleESMO gastrointestinal oncology2026
Preclinical identification and clinical validation of dynamic biomarkers for trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biomarkers predicting response to trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC) remain unclear. We identified candidate biomarkers in preclinical models and evaluated their clinical relevance. Materials and methods: Candidate biomarkers were identified through preclinical transcriptomic analyses. Serum interleukin (IL)-8, epiregulin (EREG), amphiregulin (AREG), interferon-inducible protein 16 (IFI16), and vascular endothelial growth factor A (VEGF-A) were measured in two cohorts treated with FTD/TPI+BEV or FTD/TPI alone. Samples were collected at baseline, before cycle 2, and at progression. Biomarker changes were categorized as increased or decreased. Propensity score matching was carried out, and survival outcomes were compared according to biomarker dynamics. Results: Among 112 patients, 34 matched pairs were analyzed after propensity score matching. FTD/TPI+BEV yielded longer overall survival (OS) than FTD/TPI alone [10.5 versus 6.2 months; hazard ratio (HR) 0.53]. Increased IL-8 at cycle 2 and elevated IFI16 at progression were associated with poorer prognosis, whereas decreased AREG at cycle 2 predicted improved survival. In patients with increased IL-8, OS was longer with FTD/TPI+BEV than with FTD/TPI alone (12.8 versus 5.8 months; HR 0.43). Early EREG decrease was associated with better OS only in the FTD/TPI+BEV group. No significant interaction was observed between treatment and biomarker dynamics. Conclusion: On-treatment changes in IL-8, AREG, and EREG may serve as prognostic-and potentially predictive-biomarkers of FTD/TPI efficacy in mCRC. These findings support further evaluation of biomarker-guided treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.